Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
Update: Spero Therapeutics Q3 Adj. EPS $(0.16) Beats $(0.47) Estimate
Spero Therapeutics Q3 EPS $(0.76) Misses $(0.47) Estimate
Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics to Present at Investor Conferences in November
Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.